Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The B-cell receptor (BCR) specific for the HIV-1 Envelope (Env) protein is the primary target for modern germline-targeting vaccine strategies aimed at preventing HIV-1 infection. These receptors are membrane-bound immunoglobulins on B cells that recognize the HIV-1 Env trimer, the sole viral surface protein responsible for host cell entry (Haynes et al., Nature Reviews Immunology, 2023). Because HIV-1 evolves rapidly, vaccines must stimulate B cells to produce broadly neutralizing antibodies (bNAbs) that can recognize conserved regions of the Env protein across diverse viral strains. Current therapeutic approaches involve using highly engineered protein or mRNA-based immunogens, such as eOD-GT8 60mer, to selectively engage rare precursor B cells expressing specific BCR sequences (Jardine et al., Science, 2013). By guiding the maturation of these B cells through sequential immunization, researchers hope to elicit protective immunity that the natural immune response typically fails to generate during infection. This target is central to the reductionist vaccine design approach, which focuses on specific epitopes like the CD4 binding site or the V3-glycan patch (Sok & Burton, Nature Reviews Immunology, 2018). Successful engagement of these BCRs is monitored through high-sensitivity flow cytometry and single-cell sequencing to track the expansion of specific B-cell lineages (Leggat et al., Science, 2022). Ultimately, the goal is to induce a durable and broad antibody response capable of neutralizing the vast majority of global HIV-1 variants.
Binding of engineered immunogens to specific germline or intermediate B-cell receptors to trigger B-cell activation, clonal expansion, and somatic hypermutation toward the production of broadly neutralizing antibodies (Jardine et al., Science, 2016).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on B-cell receptor specific for HIV-1 Envelope protein (HIV-1 Env-specific BCR).